$15.13
+1.75%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$14.92
From 52W high−27.81%
Volume194612.00
Market cap$1.97B
P/E (TTM)—
P/S (TTM)16.4x
Div yield—
Key dataSep 18, 2026
Open
$14.92
From 52W high
−27.81%
Volume
194612.00
Market cap
$1.97B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−44.3x
P/E (TTM)
—
RSI (14)
41.8
MomentumView details →
1D Return
+1.75%
YTD Return
−16.85%
SummaryUpdated Jun 1, 2026
Mesoblast Limited (NASDAQ:MESO) is an Australian biopharmaceutical company founded in 2004 and headquartered in Melbourne. The company specializes in developing and commercializing allogeneic cellular medicines based on mesenchymal stromal cells (MSCs), a type of adult stem cell. Mesoblast went public in 2010 and has since established itself as a pioneer in the regenerative medicine field. The company achieved a significant milestone in 2024 with the FDA approval of <b>RYONCIL</b>, the first mesenchymal stromal cell therapy approved in the United States, marking its transition from a pure development-stage company to one with commercial operations.
Similar companies
Latest newsMore news →
Mesoblast Limited reported financial results for the fiscal year ended June 30, 2026, with substantial revenue growth to US$120 million and gross profit of US$104 million.25d agoMesoblast Limited completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain, with 350 patients randomized and treated.35d ago